The development of hematologic malignancy in the presence of chronic lymphocytic leukemia (CLL) is rare. We present a case of acute myeloid leukemia (AML) with del(7q) occurring in a patient with a 4-year history of untreated CLL. Application of flow cytometry and immunohistochemistry allowed for characterization of two distinct coexisting malignant cell populations. After undergoing induction and consolidation chemotherapy, the patient achieved complete remission of AML with the persistence of CLL. Allogeneic transplantation was pursued given his unfavorable cytogenetics. Subsequent matched unrelated donor allogeneic stem cell transplantation resulted in full engraftment and complete remission, with no evidence of AML or CLL. Due to a scarcity of reported cases, insight into treatment and prognosis in cases of concurrent AML and CLL is limited. However, prognosis seems dependent on the chemosensitivity of AML. CLL did not have a detrimental effect on treatment or transplant outcome in our case. This is the first reported case of concomitant de novo AML and CLL to undergo allogeneic transplantation. The patient remained in complete hematologic and cytogenetic remission of both malignancies over a year after transplantation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5144/1658-3876.2012.165 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Venetoclax and beyond: New Horizons in CLL and AML therapy.
Expert Rev Anticancer Ther
January 2025
Department of Hematology, S. M. Goretti Hospital, Polo Universitario Pontino, Latina, Italy.
The Challenge of Diagnosing Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Report.
Anticancer Res
January 2025
Department of Hematology/Oncology, Luminis Health Anne Arundel Medical Center, Annapolis, MD, U.S.A.
Background/aim: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and highly aggressive hematologic cancer which is difficult to diagnose and has a lot of overlapping features with other diseases, particularly acute myeloid leukemia (AML). BPDCN shares several immunophenotypic markers with AML, such as CD4, CD56, CD123, and HLA-DR, stating the importance of having extending panel of specific immunohistochemical (IHC) markers.
Case Report: This report details a case of CLL who presented with worsening symptoms of recurrent infections and leukocytosis.
Background: vitamin D plays a crucial role in immune regulation, anti-inflammatory processes, and tumor suppression, but its relationship with leukemia risk remains unclear. This study aims to evaluate the causal relationship between vitamin D levels and the risk of different types of leukemia through a two-sample Mendelian randomization (MR) analysis.
Methods: data from large-scale genome-wide association studies (GWAS) were used, and genetic variants associated with vitamin D were selected as instrumental variables.
Causal relationship between branched-chain amino acids and leukemia risk: insights from a two-sample Mendelian randomization study.
Hematology
December 2024
Hematology Department, Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Nanchang, Jiangxi, People's Republic of China.
Background: Branched-chain amino acids (BCAAs), including leucine, isoleucine, and valine, are essential amino acids involved in protein synthesis, energy metabolism, and immune regulation. While BCAAs are known to influence cancer biology, their role in leukemia remains unclear. This study employs Mendelian randomization (MR) analysis to explore the causal relationship between BCAA levels and four leukemia subtypes: acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML).
View Article and Find Full Text PDFTemporal changes in the burden of leukaemia and lymphoma in the Australasia and Oceania regions, 2010-2019: an analysis of the Global Burden of Disease Study 2019.
BMJ Open
November 2024
Deakin Health Economics, Deakin University School of Health and Social Development, Burwood, Victoria, Australia.
Article Synopsis
- This study investigates the prevalence and trends of leukaemias and lymphomas in Australasia and Oceania from 2010 to 2019, focusing on key subtypes like AML and NHL.
- Using data from the Global Burden of Disease 2019, the research analyzes incidence, prevalence, disability-adjusted life years (DALYs), and deaths across different age groups and sexes.
- Findings indicate that AML and NHL are the leading cancers in both regions, with Australasia showing overall increases in disease burden during the study period, while Oceania has mixed trends in mortality and prevalence across various leukaemias and lymphomas.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!